HomeCompareRSLS vs PLD

RSLS vs PLD: Dividend Comparison 2026

RSLS yields 51.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.09M in total portfolio value· pulled ahead in Year 8
10 years
RSLS
RSLS
● Live price
51.02%
Share price
$3.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$415.3K
Annual income
$85,519.64
Full RSLS calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — RSLS vs PLD

📍 PLD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSLSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSLS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSLS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSLS
Annual income on $10K today (after 15% tax)
$4,336.73/yr
After 10yr DRIP, annual income (after tax)
$72,691.69/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,395,279.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSLS + PLD for your $10,000?

RSLS: 50%PLD: 50%
100% PLD50/50100% RSLS
Portfolio after 10yr
$3.46M
Annual income
$2,670,977.91/yr
Blended yield
77.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RSLS
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.1
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSLS buys
0
PLD buys
0
No recent congressional trades found for RSLS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSLSPLD
Forward yield51.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$415.3K$6.50M
Annual income after 10y$85,519.64$5,256,436.18
Total dividends collected$332.9K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: RSLS vs PLD ($10,000, DRIP)

YearRSLS PortfolioRSLS Income/yrPLD PortfolioPLD Income/yrGap
1$15,802$5,102.04$11,255$555.24+$4.5KRSLS
2$24,443$7,534.83$13,062$1,018.59+$11.4KRSLS
3$37,047$10,892.59$15,903$1,926.67+$21.1KRSLS
4$55,069$15,429.12$20,839$3,823.32+$34.2KRSLS
5$80,358$21,434.63$30,464$8,166.08+$49.9KRSLS
6$115,215$29,231.87$52,054$19,457.30+$63.2KRSLS
7$162,450$39,169.84$109,886$54,188.93+$52.6KRSLS
8← crossover$225,437$51,615.25$304,030$186,451.18$78.6KPLD
9$308,160$66,942.06$1,166,125$840,813.32$858.0KPLD
10$415,251$85,519.64$6,504,190$5,256,436.18$6.09MPLD

RSLS vs PLD: Complete Analysis 2026

RSLSStock

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Full RSLS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RSLS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSLS vs SCHDRSLS vs JEPIRSLS vs ORSLS vs KORSLS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.